Zymeworks Inc. (ZYME)
| Market Cap | 1.80B +29.7% |
| Revenue (ttm) | 265.97M +97.8% |
| Net Income | 43.31M |
| EPS | 0.56 |
| Shares Out | 69.03M |
| PE Ratio | 46.52 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,085,747 |
| Open | 25.65 |
| Previous Close | 25.84 |
| Day's Range | 24.86 - 26.24 |
| 52-Week Range | 21.52 - 31.97 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 43.29 (+66.24%) |
| Earnings Date | Nov 9, 2026 |
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead pr... [Read more]
Financial Performance
In 2025, Zymeworks's revenue was $105.97 million, an increase of 38.87% compared to the previous year's $76.30 million. Losses were -$81.13 million, -33.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $43.29, which is an increase of 66.24% from the latest price.
News
Zymeworks Transcript: Jefferies Global Healthcare Conference
ZW209’s Roche partnership, a diversified capital strategy and novel multi-specific programs are central to the outlook. Key catalysts include zanidatamab studies and a 2027 phase III pasritamig readout.
Zymeworks management to meet with B. Riley
Group Dinner Meeting to be held in London, England on November 16 hosted by B. Riley.
Zymeworks announces $200M share repurchase program
Zymeworks (ZYME) announced that its Board of Directors has authorized a second 2026 share repurchase program under which the company may repurchase up to $200M of its outstanding common stock.
Zymeworks Announces $200 Million Share Repurchase Authorization
Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunit...
Zymeworks price target raised to $39 from $32 at Citizens
Citizens analyst Reni Benjamin raised the firm’s price target on Zymeworks (ZYME) to $39 from $32 and keeps an Outperform rating on the shares. The firm’s outlook is supported by…
Zymeworks Transcript: Stifel 2026 Healthcare Conference 2026
Zanidatamab’s potential $500M–$900M in royalty income supports a flexible model combining R&D, buybacks and opportunistic M&A. Pipeline priorities include partnering ZW191, advancing differentiated programs and exploring investor-backed spinouts for pan-RAS ADCs.
Zymeworks price target raised to $44 from $39 at Citi
Citi raised the firm’s price target on Zymeworks (ZYME) to $44 from $39 and keeps a Buy rating on the shares. The company upped its 2026 revenue guidance to reflect…
Zymeworks reports Q3 EPS $2.28, consensus $2.19
Reports Q3 revenue $256.46M, consensus $221.01M. “We are entering the next phase of Zymeworks (ZYME) growth with a fundamentally stronger and more diversified business. The transformation of Zymeworks...
Zymeworks price target raised to $56 from $55 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $56 from $55 and keeps a Buy rating on the shares following the Q3 report.
Zymeworks price target raised to $39 from $34 at TD Cowen
TD Cowen raised the firm’s price target on Zymeworks (ZYME) to $39 from $34 and keeps a Buy rating on the shares. The company raised FY26 revenues and adjusted EBITDA…
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip...
Zymeworks Earnings release: Q3 2026
Zymeworks released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Zymeworks Quarterly report: Q3 2026
Zymeworks has published its Q3 2026 quarterly earnings report on November 9, 2026.
Zymeworks Transcript: Investor update
The Roche deal funds ZW209 development while preserving milestone and royalty upside. ZW191 showed activity at both doses in heavily pretreated ovarian cancer, and partner data reported 27-month median OS for the ZIIHERA triplet in first-line advanced GEA.
Zymeworks Press release: Investor update
Zymeworks issued a press release on October 27, 2026, disclosing material business information to investors.
Zymeworks Slides: Investor update
Zymeworks has posted slides in relation to its latest quarterly earnings report, which was published on October 27, 2026.
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Zymeworks Proxy statement: Proxy filing
Zymeworks filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
Zymeworks Proxy statement: Proxy filing
Zymeworks filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
Zymeworks presents new clinical data from Phase 1 study of ZW191
Zymeworks (ZYME) presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRalpha-targeting antibody-drug conjugate, ADC, at the Europ...
Zymeworks presents new clinical data on Phase 1 study of ZW191
Zymeworks (ZYME) presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRalpha-targeting antibody-drug conjugate, ADC, at the Europ...
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe...
Zymeworks price target raised to $52 from $50 at Jefferies
Jefferies raised the firm’s price target on Zymeworks (ZYME) to $52 from $50 and keeps a Buy rating on the shares. The company and Roche (RHHBY) entered into an exclusive…
Zymeworks signs collaboration and license agreement with Roche for ZW209
Zymeworks (ZYME) announced that it has entered into a global license and collaboration agreement with Roche (RHHBY) for the research, development and commercialization of ZW209, a T cell engager targe...
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe...